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ABSTRACT 
Objectives: The aims of this study were to investigate he pharmacokinetic 
(PK) properties of aripiprazole in the steady state in Han Chinese adults with 
schizophrenia and to compare them between Han Chinese and white popula- 
tions described in the literature. 
Methods: This prospective, open-label, pilot study was conducted at the 
Mental Health Institute, Xiang-ya Second Hospital, Central South University, 
Changsha, China. Male and female hospitalized patients aged 18 to 45 years 
diagnosed with Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-llO-defined schizophrenia, with a Positive and Negative Syndrome 
Scale (PANSS) total score >60 (indicating schizophrenia of at least mild sever- 
ity) were eligible. On study days 1 and 2, patients were pretreated with aripipra- 
zole 10 mg PO QD, followed by 10 mg ql2h on days 3 to 21. Blood samples 
were drawn for analysis on day 21 before dosing and 1, 3, 4, 5, 12, 24, 48, 72, 96, 
144, and 192 hours after the morning dosing of aripiprazole on day 21. Patients 
received low-dose (25-100 mg/d) clozapine on day 25 until day 28. The samples 
were assessed using high-performance liquid chromatography-mass spectrom- 
etry and compartment model analysis for aripiprazole. PK properties included 
mean residence time (MRT), steady-state Cma x (Css max)' time to Css max (Tmax)' 
elimination tl/2, apparent oral clearance (CL/F), and apparent volume of distri- 
bution (V/F). Adverse effects were monitored using physical examination 
(including vital sign measurements), electrocardiography, electroencephalog- 
raphy, and clinical laboratory testing (including biochemistry, hematology, 
and urinalysis) at baseline and at the end of the study. Patients were asked 
about adverse events on days 1 to 7 and at random intervals thereafter. 
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Patients were also instructed to report any spontaneous symptoms they 
experienced. 
Results: Twelve patients were enrolled (6 men, 6 women; mean [SD] age, 26.1 
[7.0] years; mean [SD] weight, 56.6 [9.0] kg; mean [SD] PANSS score, 116.8 
[ 12.2]). Aripiprazole xhibited linear kinetic characteristics on a 2-compartment 
model. After multiple oral doses (10 mg q12h), the mean (SD) tl/2, Css max, Tmax' 
MRT, WE and CL/F were 62.2 (9.0) hours, 557.3 (135.5) ng/mL, 2.6 (1.1) hours, 
84.5 (11.2) hours, 173 (48) L, and 1.9 (0.5) L/h, respectively. In Chinese patients, 
the tl/2 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max 
values were numerically higher (557.3 [135.5] vs 393 [181] ng/mL); and V/F and 
CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] 
vs 3.4 [ 1.6] L/h) compared with healthy white male volunteers. Adverse effects 
were mild to moderate: lightheadedness (5 of 12 patients), somnolence (3), 
tachycardia (3), hypodynamia (2), and extrapyramidal symptoms (EPS) (1). The 
EPS (convulsive movement of the muscles related to the larynx) led to one 
patient's discontinuation f the study. 
Conclusions: In this small pilot study of the PK properties of aripiprazole 
10 mg PO q12h in Han Chinese patients with schizophrenia, the mean tl/2 value 
was numerically similar to that previously reported in a population of healthy 
white male volunteers. However, the mean Css max value was numerically higher, 
and V/F and CL/F values were numerically ower, compared with those in healthy 
white male volunteers. (Curr Ther Res Clin Exp. 2006;67:258-269) Copyright © 
2006 Excerpta Medica, Inc. 
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INTRODUCTION 
Aripiprazole, an oral psychotropic, 1 is a quinolinone derivative with a pharma- 
cologic profile that differs from other currently available typical and atypical 
antipsychotics. Aripiprazole demonstrates mixed dopamine-2 (D2) and sero- 
tonin (5-HT) 1A receptor agonist-antagonist activity that is hypothesized to 
improve positive and negative symptoms of schizophrenia. 2-4As a partial ago- 
nist, aripiprazole is postulated to stabilize the dopaminergic system, improving 
the symptoms of schizophrenia without producing unwanted antagonist activ- 
ity associated with adverse ffects, such as extrapyramidal symptoms (EPSs) 
and hyperprolactinemia, s Aripiprazole also has been found to have partial 
agonist activity at the 5-HT1A receptor 3 and antagonistic activity at the 5-HT2A 
receptor. 4 It has been postulated that partial agonist activity at the 5-HTIA 
receptor might contribute to improvement in anxiety, depression, negative 
symptoms (eg, apathy, lack of interpersonal communications, lack of drive), 
and fewer EPSs. 3 Aripiprazole has been found to have efficacy measured by 
Positive and Negative Syndrome Scale (PANSS), 6 Clinical Global Impressions 
(CGI)-Severity of Illness, and mean CGI-Improvement scores in short- (4 weeks) 
and long-term (26 and 52 weeks) clinical studies involving patients with schizo- 
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phrenia or schizoaffective disorders. 7-1° Aripiprazole treatment was found to be 
well tolerated in those studies, with a low risk for EPSs (3%-10%), weight gain 
(5%-14%), and hyperprolactinemia (3.4%). 7-1° 
Aripiprazole is well absorbed, with Cma xplasma occurring within 3 to 5 hours 
with the absolute oral bioavailability of the tablet formulation being 87%. 1 
Aripiprazole can be administered with or without food. In vitro data suggest 
that aripiprazole is extensively metabolized via the hepatic cytochrome P-450 
(CYP) 3A4 and CYP2D6 isozyme pathways. 11 Mean tl/2 values have been found 
to be 75 and 94 hours for aripiprazole and the active metabolite, dehydroari- 
piprazole, respectively. Steady-state plasma concentrations are attained within 
14 days of the start of treatment for aripiprazole and dehydroaripiprazole. 1 
Mallikaarjun et a112 reported the results from 2 randomized, placebo- 
controlled, double-blind studies that assessed the pharmacokinetic (PK) prop- 
erties and tolerability of aripiprazole at 5 mg/d, and 10, 15, and 20 mg/d in 
39 healthy male volunteers. The 2 studies found that aripiprazole had a linear 
PK profile over the 5- to 30-mg/d dose range studied. Steady state Cma x (Css max) 
(day >_14), ranged from 98 to 452 ng/mL, with corresponding time to Css max (Tmax) 
values of 3 to 5 hours, respectively. The terminal tl/2 ranged from 48 to 
68 hours across doses. A randomized, double-blind, parallel-group, inpatient, pilot 
study by Auby et a113 in a white population found that the Css max of aripiprazole 
and its metabolites increased proportionately with dose, but no detailed PK 
properties were reported. 
Although the PK properties of aripiprazole have been reported in healthy 
white male volunteers, 12aripiprazole has been found to have large between- 
subject PK variability. Based on a MEDLINE/PubMed search of the literature 
(key terms: aripiprazole, Han Chinese, schizophrenic, and pharmacokinetics; 
years: 1990-2006), data comparing the PK properties of aripiprazole in schizo- 
phrenic patients versus healthy volunteers are limited. In addition, although a 
PK assessment of aripiprazole found no evidence of clinically significant race- 
related differences, 1 12 the aripiprazole PK properties in Han Chinese patients 
with schizophrenia have not been reported. Therefore, the aims of the present 
study were to investigate the PK properties of aripiprazole at the steady state 
in Han Chinese patients with schizophrenia nd compare them between Han 
Chinese and white male populations described in the literature. 12 
PATIENTS AND METHODS 
This prospective, open-label, pilot study was conducted at the Mental Health 
Institute, Xiang-ya Second Hospital, Central South University, Changsha, China. 
The local ethics committee reviewed and approved the study protocol. Written 
informed consent was obtained from all patients before involving them in any 
study-related procedures. This study complied with the principles of the 
Guideline for Good Clinical Practice 14 and the World Medical Association's 
Declaration of Helsinki and its amendments. 15 
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Inclusion and Exclusion Criteria 
Male and female hospitalized Han Chinese patients aged 18 to 45 years, with 
body weight within 10% of ideal (which was calculated using the following formula: 
[height (cm) - 80] × 0.7 kg for men and [height (cm) - 70] × 0.6 kg for women 16) 
and with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) 17 defined diagnosis of schizophrenia with a PANSS 6 total score >60 (indi- 
cating schizophrenia of at least mild severity) were eligible. The PANSS is an 
interview-based assessment of the severity of positive, negative, and general psy- 
chopathology in adults with schizophrenia, composed of 3 scales and 30 items 
(positive scale, 7 items; negative scale, 7 items; general psychopathology scale, 
16 items), with individual items rated on an anchored scale of 1 (absent) to 
7 (extreme) (scale: <90 = mild; 90-119 = moderate; 120-150 = severe). 6 
Patients with any of the following criteria were excluded from the study: 
presence of cardiovascular disease, hepatic abnormalities, renal disorder, 
digestive tract disease, or other concurrent medical conditions that might inter- 
fere with the assessment; reatment with any inhibitor or inducer of CYP3A4 
(eg, ketoconazole, carbamazepine) or CYP2D6 (eg, quinidine, fluoxetine, parox- 
etine) 1 in the previous 2 weeks; treatment failure with clozapine; treatment with 
any concomitant medications that might interfere with the metabolism of ari- 
piprazole; in women, pregnancy or breastfeeding; a positive test for drugs of 
abuse on urinalysis; history of alcohol abuse, illicit drug abuse, or drug allergy; 
a smoking habit; a positive test for HIV; donation of blood or plasma in the pre- 
vious 90 days; and/or participation in another investigational drug study within 
the previous 30 days. 
Study Drug Administration 
Patients were enrolled and received pretreatment on study days 1 and 2 with 
aripiprazole 10 mg PO QD, followed by aripiprazole 10 mg ql2h (7 AM and 7 PM) 
on days 3 to 21. Patients were hospitalized throughout the treatment period. On 
day 25, aripiprazole was replaced by low-dose (25-100 rag/d) clozapine until 
day 28 for determination of the tl/2 of aripiprazole. 
Blood Sampling 
Blood samples for PK analysis were drawn by a nurse before dosing on day 21 and 
at 1, 3, 4, 5, 12, 24, 48, 72, 96, 144, and 192 hours after the morning dosing of aripip- 
razole on day 21. To assess the steady-state of aripiprazole, blood samples were 
drawn before the morning dose on days 18 through 20. The samples were collected 
in disposable thylenediaminetetracetic acidtubes and left at room temperature 
(25°C) for not longer than 1 hour and then centrifuged at 3000g for 5 minutes. The 
plasma was transferred to plastic tubes and stored frozen at -80°C until analysis. 
Bioanalytic Methods 
Plasma aripiprazole concentrations were determined using high-performance 
liquid chromatography-electrospray m ss spectrometric (HPLC-MS) assay 
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(Waters 2690 Micromass ZQ, Wythenshawe, Manchester, United Kingdom; 
Hypersil Gold C18 column, Thermo Electron Corporation, Waltham, Massachu- 
setts). Plasma samples containing aripiprazole were prepared for analysis by 
the addition of methanol (Tedia Company Inc., Fairfield, Ohio)-containing inter- 
nal standard (estazolam [purity, 99.9%], National Institute for the Control of 
Pharmaceutical nd Biological Products, Beijing, China). Extraction and chro- 
matography were based on the published method of Kubo et al. ~8 Plasma sam- 
pies were vortexed briefly and aliquots (150 IJL) were transferred to glass cen- 
trifuge tubes, then alkalinized by the addition of 30 IJL aqueous ammonia (Hunan 
Chemical Reagent Factory, Changsha, China). Methyl-t-butyl ether (Tedia 
Company Inc.) 4 mL as extractant was added to the samples. Supernatant was 
transferred to a clean tube and evaporated in nitrogen in a 50°C water bath. The 
residue was dissolved in 150 IJL of mobile phase containing 0.1% trifluoroacetic 
acid (Hunan Chemical Reagent Factory). Five microliters of sample were inject- 
ed into the HPLC-MS system, with acetonitrile (Tedia Company Inc.) 30-mmol/L 
ammonium acetate containing 0.1% formic acid, 58:42 (v/v), as mobile phase. The 
protonated analyte was quantified by selected ion recording with a quadrupole 
mass spectrometer (Waters 2690 Micromass ZQ) in positive-ion mode. Target ions 
were monitored at 448 and 450 m/z (the mass/charge ratio) for aripiprazole and 
295 m/z for estazolam. Calibration plots were linear over the concentration range 
of 19.9 to 1119.6 ng/mL. The lower limit of quantization was 19.9 ng/mL. Intraday 
and interday precision (CV%) and accuracy (RE%) for the 3 quality-control 
plasma samples (37.3, 124.4, and 622.0 ng/mL, respectively) (Blood Center, 
Shanghai, China) ranged between 2.5% and 9.0% and between 1.3% and 3.5%, 
respectively. Extraction recovery of aripiprazole from plasma was in the range 
of 75.8% to 84.1%. Plasma aripiprazole concentrations were determined in the 
laboratory at the hospital. 
Pharmacokinet ic  Calculation 
The plasma concentration-time curves for each patient were analyzed using 
3P97 software (Chinese Pharmacological Society and the Mathematic and 
Pharmaco-Professional Committee, Beijing, China). This model was based on all 
plasma concentrations collected on days 21 to°28. The PK compartment model 
that best fit the data was selected based on goodness of fit (r 2) and the Akaike 
information criterion. 
Following oral administration, a 2-compartment open model was found to best 
fit the data with the biexponential equation 
C = Ne-'ka t + Le -~t + Me -I~t, 
where C is the plasma aripiprazole concentration; N and k a a re  the intercept and 
slope, respectively, of the absorption phase; L and a are the intercept and slope, 
respectively, ofthe distribution phase; M and fl are the intercept and slope, respec- 
tively, of the elimination phase; and t is time. The tl/2 of the k a phase (tl/2 k~), 
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~¢ phase (tl/2 ~), and [~ phase (tl/2 ~); mean residence time (MRT); distribution 
rate constant for drug transfer from the central to peripheral compartment 
(k12); transfer rate constant from peripheral to central compartment (k21); 
and elimination rate constant (kl0) were calculated using the 3P97 software. 
Values for steady-state Cmi n (Css min)' steady-state Cma x, and time to Css max 
were determined from the observed data. After study drug administration 
on day 21, the steady-state AUCs from time 0 to 12 hours (AUCss 0-12), 0 to 
192 hours (AUCss 0-192), and 0 to infinity (AUCs~ 0 J  were calculated using a 
trapezoidal method. The mean plasma concentration for the 12-hour drug 
administration interval (Css av) was calculated using the equation Css av = 
AUCss 0_12/12. The oral clearance at steady state (CL/F) was calculated using 
the equation CL/F = 10 mg/(AUC~ 0_12)- The apparent volume of distribution 
(V/F) was calculated as V/F = CL/[3. The fluctuation percentage (FI) was cal- 
culated as FI = ([Css max] - [C~ min])/(Css max)" 
Tolerability Assessment 
Adverse effects were monitored using physical examination 0ncluding vital 
sign measurements), electrocardiography, electroencephalography, and clinical 
laboratory testing (including biochemistry, hematology, and urinalysis) at base- 
line and at the end of the study. Investigators also questioned patients and 
observed any signs or symptoms on study days 1 to 7, and at random intervals 
thereafter. The patients were also instructed to report any spontaneous symp- 
toms they experienced uring the study period. 
Statistical Analysis 
Results were expressed as mean (SD). Sex differences in PK properties were 
assessed by comparing Tma x using the Wilcoxon signed rank test, and, for the 
other variables, log-transformed data were compared using the independent- 
samples t test. Achievement of a steady state was determined using 1-way 
analysis of variance to compare Cmi n levels on days 18 to 21. Analyses were per- 
formed using SPSS version 11.0 (SPSS Inc., Chicago, Illinois). A 2-tailed P value 
was used, and the level of statistical significance was set at P < 0.05. 
RESULTS 
Patient Population 
Twelve patients participated in the study (6 men, 6 women; mean [SD] age, 
26.1 [7.0] years; mean [SD] weight, 56.6 [9.0] kg; mean [SD] PANSS score, 116.8 [12.2]); 
11 completed it. One patient discontinued treatment due to the onset of EPS. 
The characteristics of the study patients are shown in Table I. 
Pharmacokinetic Properties 
Steady state was reached in all subjects by day 21. The mean plasma aripipra- 
zole concentrations on days 21 to 28 are shown in the figure. Other PK proper- 
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Figure. Mean (SD) plasma concentrations after multiple (19 days [steady state]) 
oral doses of aripiprazole 10 mg q12h in Han Chinese patients with schizo- 
phrenia (N = 11). 
ties are shown in Table II. After multiple oral doses (10 mg ql2h), the mean (SD) 
tl/213, Css max, Tmax, MRT, V/F, and CL/F were 62.2 (9.0) hours (range, 42.6- 
77.0 hours), 557.3 (135.5) ng/mL, 2.6 (1.1) hours (range, 1-4 hours), 84.5 (11.2) hours, 
173 (48) L, and 1.9 (0.5) L/h, respectively. No significant sex differences in PK 
results were found (Table III). 
In Han Chinese patients, the tl/2 values were numerically similar (62.2 [9.0] vs 
68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 
393 [181] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] 
vs 196 [66] L; CL/F" 1.9 [0.5] vs 3.4 [1.6] L/h) when compared with healthy white 
male volunteers. ]2 
Tolerabil ity 
All 12 patients were included in the tolerability analysis. In the study, 
adverse effects generally occurred early in the drug administration period 
and were mild to moderate. The most common adverse events were light- 
headedness (5 of 12 patients), somnolence (3), tachycardia (3), hypody- 
namia (2), and an EPS (1). The EPS, a convulsive movement of the muscles 
related to the larynx, led to discontinuation. No clinically significant changes 
in other tolerability parameters were reported. 
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Table II. Steady-state pharmacokinetic properties after multiple oral doses of aripipra- 
zole 10 mg PO q12h in Han Chinese patients with schizophrenia (N = 11). 
Values are mean (SD). 
Property Value Property Value 
~, h -I 0.309 (0.227) WF, L 173 (48) 
[3, h -I 0.011 (0.002) CLIE Llh 1.9 (0.5) 
klo, h -I 0.024 (0.018) Css rain, nglmL 388.4 (I 08.7) 
k12, h -I 0.114 (0.100) Css max, nglmL 557.3 (I 35.5) 
k21, h -I 0.182 (0.146) Css av, nglmL 457.7 (I 15.8) 
t l l  2 ka , h 0.3 (0.2) AUCss o-12' nglmL • h -I 5492 (I 390) 
t l l  2 ~, h 4.4 (3.5) AUC~ o-192, nglmL • h -I 35,171 (11,588) 
Tmax, h 2.6 (I . I )  AUCss o-~ ng lml  • h -I 38,678 (I 2,639) 
tI12 I~' h 62.2 (9.0) FI, % 30.4 (8.2) 
MRT, h 84.5 (11.2) 
= slope of the distribution phase; 113 = slope of the elimination phase; klo = elimination rate constant; 
k12 = distribution rate of drug transfer from the central compartment to the peripheral compartment; k21 = 
transfer rate constant from the peripheral compartment o the central compartment; tl/2 k~ = half-life 
of the k a phase, where k a is the slope of the absorption phase; tl/2 ~ = half-life of the c¢ distribution phase; 
Tma x = time to Crnax at steady state (Css max); tl/2 B = half-life of the ~ elimination phase; MRT = mean resi- 
dence time; V/F = apparent volume of distribution; CI_/F = oral clearance at steady state; Css rain = Cmin 
at steady state; Css av = mean plasma concentration over the 1 2-hour drug administration interval; 
AUCss 0-12 = AUC from time 0 to 12 hours at steady state; AUCss o-192 = AUC from time 0 to 192 hours at 
steady state; AUCss 0~ = AUC from time 0 to infinity at steady state; FI = fluctuation percentage. 
DISCUSSION 
The recommended dosage of aripiprazole is 10 to 30 mg/d. 1 The results of this 
study suggest hat the tested dosage of aripiprazole, 10 mg q12h, was well- 
tolerated in these Han Chinese patients with schizophrenia. Based on previous 
reports of the tl/2 of aripiprazole, 1 it might be administered once daily. For the 
determination of possible treatment-emergent adverse ffects 2° and their dose- 
response relationships, patients received aripiprazole 10 mg QD for 2 days at 
the beginning of treatment, and 10 mg q12h thereafter. 
Because patients discontinued aripiprazole from days 21 to 28 for the deter- 
mination of aripiprazole tl/2, clozapine 25 to 100 mg/d was administered as 
replacement treatment from observation day 25. In an in vitro study, Shin et a111 
found that all antipsychotic drugs tested competitively inhibited dextromethor- 
phan O-demethylation, a selective marker for CYP2D6, in a concentration- 
dependent manner. The therapeutic plasma clozapine concentration had been 
reported as 1.377 pmol/L, u Therefore, the predicted percentage of inhibition of 
CYP2D6 was 3.11%. Based on that prediction, Shin et al H hypothesized that 
clozapine would not significantly inhibit CYP2D6 in vivo. Clozapine was not 
found to notably inhibit CYP3A4. Those findings suggested that clozapine at 
1.377 pmol/L was not associated with a PK drug interaction with aripiprazole 
(ie, clozapine would not interfere with the tl/2 determination of aripiprazole). 
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Table III. Steady-state pharmacokinetic properties of aripiprazole 10 mg PO q12h 
in female and male Han Chinese patients with schizophrenia.* Values are 
mean (SD). 
Female Male 
Parameter (n = 6) (n = 5) 
tw2 ka' h 0.2 (0.2) 0.3 (0.2) 
tl/2 ~, h 5.9 (3.8) 2.8 (2.5) 
t l /2  [~, h 64.8 (4.9) 59.2 (12.3) 
MRT, h 86.6 (7.3) 82.1 (15.3) 
Tmax, h 2.7 (1.4) 2.6 (0.9) 
Css rn~n, ng/mL 387.5 (100.0) 389.5 (133.3) 
Css max' ng/mL 526.1 (131.7) 594.8 (144.8) 
Css av, ng/mL 453.7 (106.9) 462.5 (138.6) 
V/F, L 166 (56) 181 (52) 
CL/F, L/h 1.9 (0.5) 1.9 (0.5) 
AUCss o-12, ng/mL, h -1 5444 (1282) 5550 (1663) 
AUCss o-~, ng/mL, h -1 40,481 (13,142) 36,514 (13,145) 
t1/2 k~ = half-life of the k a phase, where k a is the slope of the absorption phase; tl/z ~ = half-life of the 
a distribution phase; tl/20 = half-life of the [3 elimination phase; MRT = mean residence time; Tma x = 
time to Cma x at steady state (C ); C . = C • at steady state; C v = mean plasma concentration 
over the 12-hour drug administS~amt~on in"[ernr~al; V/~ m apparent volumeS~f distribution; CL/F = oral clear- 
ance at steady state; AUCss o_12 = AUC from time 0 to 12 hours at steady state; AUCss 0~ = AUC from 
time 0 to infinity at steady state. 
• No significant between-sex differences were found. 
In the present study, the PK properties of aripiprazole determined from these 
Han Chinese patients with schizophrenia suggest that the absorption rate of the 
drug was relatively rapid compared with the distribution and elimination rates. 
The tl/2 obtained using this model was similar to those reported previously by 
Mallikaarjun et aP 2 but the mean Css max and Css min values were 557.3 and 
388.4 ng/mL, respectively, which were higher than those previously reported and 
might have been associated with the lower V/F and CL/F values we found. Those 
differences in the PK properties of aripiprazole between Han Chinese schizo- 
phrenic patients and those in a population of healthy white male volunteers 
reported previously 12 might be explained by the differences in mean body mass 
index between these 2 populations. Another possible reason for the differences 
might be that all of the patients in the present study achieved steady state by 
day 21, whereas 2of 6 subjects (20-mg/d group) in the literature 12 achieved plasma 
concentrations only within 90% of steady state by the end of the study (day 14). 
Study Limitat ions and Future Direction 
The results of the present study should be interpreted with caution due to 
the following limitations. Though this study examined both men and women, 
the comparison group consisted of only white males. The sample size was 
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small. The dose studied did not include the 10- or 30-mg/d dosages recom- 
mended by the manufacturer. We examined only this fixed dosage due to dif- 
ficulty in collecting patient data. Thus, future studies should extend the 
dosage range of aripiprazole. They should also include investigations f meta- 
bolic profile and drug interactions of aripiprazole in Han Chinese patients with 
schizophrenia. 
CONCLUSIONS 
In this small pilot study of the PK properties of aripiprazole 10 mg PO ql2h in 
Han Chinese patients with schizophrenia, the mean tl/2 value was numerically simi- 
lar to that previously reported in a population of healthy white male volunteers. 
However, the mean Css max value was numerically higher, and V/F and CL/F values 
were numerically lower, compared with those in healthy white male volunteers. 
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